For US Health Care Professionals

Introducing LGSOC
Diagnosis
Management
Emerging Treatments
Resources
Sign Up

500

Sorry, the server has encountered an internal error and was unable to complete your request

Please try reloading the page and if it doesn’t work, try again in 30 minutes.

References

Matsuo K, Machida H, et al. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018;29(1):e15. doi: 10.3802/jgo.2018.29.e15.
Babaier A, Mal H, Alselwi W, Ghatage P. Low-Grade Serous Carcinoma of the Ovary: The Current Status. Diagnostics (Basel). 2022 Feb 10;12(2):458. doi: 10.3390/diagnostics12020458. PMID: 35204549; PMCID: PMC8871133.
Grisham RN, Manning‐Geist BL, Chui MH. The highs and lows of serous ovarian cancer. Cancer. 2023;1‐8. doi:10.1002/cncr.34903
Zwimpfer TA, Tal O, Geissler F, Coelho R, Rimmer N, Jacob F, Heinzelmann-Schwarz V. Low grade serous ovarian cancer – A rare disease with increasing therapeutic options. Cancer Treat Rev. 2023 Jan;112:102497. doi: 10.1016/j.ctrv.2022.102497. Epub 2022 Dec 10. PMID: 36525716
Grisham RN, Slomovitz BM, Andrews N, et al. Low-grade serous ovarian cancer: Expert consensus report on the state of the science
Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457-462. doi:10.1016/j.ygyno.2016.01.022
Schmeler KM, Sun CC, Bodurka DC, et al. Neoadjuvant chemotherapy for low-grade serous carcinoma of the ovary or peritoneum. Gynecol Oncol. 2008;108:510-514. doi:10.1016/j.ygyno.2007.11.013
Harvard Health
Ovarian Cancer, Version 3.2.0.22. Featured Updates to the NCCN Guidelines. Natl Compr Canc Netw 2022;20(9):972–980 doi: 10.6004/jnccn.2022.0047
Malpica A, Deavers MT, Lu K, Bodurka DC, Atkinson EN, Gershenson DM, Silva EG. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004 Apr;28(4):496-504. doi: 1097/00000478-200404000-00009. PMID: 15087669
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465. doi:10.1158/1078-0432.CCR-21-4183

Vang R, Shih IeM, Kurman RJ. Ovarian low-grade and high-grade serous carcinoma: pathogenesis, clinicopathologic and molecular biologic features, and diagnostic problems. Adv Anat Pathol. 2009;16(5):267-282. doi:10.1097/PAP.0b013e3181b4fffa
Babaier A, Mal H, Alselwi W, Ghatage P. Low-grade serous carcinoma of the ovary: The current status. Diagnostics (Basel). 2022;12(2):458. doi:10.3390/diagnostics12020458
Ali RH, Kalloger SE, Santos JL, et al. Stage II to IV low-grade serous carcinoma of the ovary is associated with a poor prognosis: a clinicopathologic study of 32 patients from a population-based tumor registry. Int J Gynecol Pathol. 2013;32(6):529-535.
Grabowski JP, Harter P, Heitz F, et al. Operability and chemotherapy responsiveness in advanced low-grade serous ovarian cancer. An analysis of the AGO Study Group metadatabase. Gynecol Oncol. 2016;140:457-462. doi:10.1016/j.ygyno.2016.01.022
Matsuo K, Machida H, Grubbs B, et al. Trends of low-grade serous ovarian carcinoma in the United States. J Gynecol Oncol. 2018;29(1):e15. doi:10.3802/jgo.2018.29.e15
Plaxe SC. Epidemiology of low-grade serous ovarian cancer. Am J Obstet Gynecol. 2008 Apr;198(4):459.e1-8; discussion 459.e8-9.doi: 10.1016/j.ajog.2008.01.035
Certain symptoms may be early signs of ovarian cancer. Harvard Health. January 20, 2017. Accessed August 7, 2023. https://www.health.harvard.edu/cancer/certain-symptoms-may-be-early-signs-of-ovarian-cancer
Gockley A, Melamed A, Bregar AJ, et al. Outcomes of women with high-grade and low-grade advanced-stage serous epithelial ovarian cancer. Obstet Gynecol. 2017;129:439-447. doi:10.1097/AOG.0000000000001867
Malpica A, Deavers MT, Lu K, et al. Grading ovarian serous carcinoma using a two-tier system. Am J Surg Pathol. 2004;28(4):496-504. doi:10.1097/00000478-200404000-00009
Alcid J, Shahin MS. Low-grade serous carcinoma of the ovary: A case series and literature review. Case Rep Images Oncology. 2018;4:100052Z10JA2018. doi:10.5348/100052Z10JA2018CS
Grisham RN, Slomovitz BM, Andrews N, et al. Low-grade serous ovarian cancer: expert consensus report on the state of the science. Published on Aug 17, 2023. Int J Gynecol Cancer. 2023;33(9):1331-1344. doi:10.1136/ijgc-2023-004610
Slomovitz B, Gourley C, Carey MS, et al. Low-grade serous ovarian cancer: State of the science. Gynecol Oncol. 2020;156(3):715-725. doi:10.1016/j.ygyno.2019.12.033
Banerjee SN, Ring KL, Nieuwenhuysen EV, et al. Initial efficacy and safety results from ENGOT-ov60/GOG-3052/RAMP 201: A phase 2 study of avutometinib (VS-6766) 6 defactinib in recurrent low-grade serous ovarian cancer (LGSOC). J Clin Oncol. 41. No 16_suppl (June 1, 2023) 5515-5515.
Manning-Geist B, Gordhandas S, Liu YL, et al. MAPK pathway genetic alterations are associated with prolonged overall survival in low-grade serous ovarian carcinoma. Clin Cancer Res. 2022;28:4456-4465. doi:10.1158/1078-0432.CCR-21-4183

Terms of Use
Copyright Statement
Privacy Policy
Contact Us

© 2023 Verastem, Inc. All Rights Reserved.

The Verastem Oncology name and logo are trademarks of Verastem, Inc. All other trademarks mentioned on this website are property of their respective owners.